| Literature DB >> 34133077 |
Sebastian J Theobald1,2, Alexander Simonis1,2, Theodoros Georgomanolis3, Christoph Kreer4, Matthias Zehner4, Hannah S Eisfeld1,2, Marie-Christine Albert5,6, Jason Chhen1,2, Susanne Motameny3, Florian Erger3,7, Julia Fischer1,2,8, Jakob J Malin1,2, Jessica Gräb1,2, Sandra Winter1,2, Andromachi Pouikli9, Friederike David3, Boris Böll1, Philipp Koehler1,2,5, Kanika Vanshylla4, Henning Gruell4, Isabelle Suárez1,8, Michael Hallek1, Gerd Fätkenheuer1,8, Norma Jung1,8, Oliver A Cornely1,2,5,8, Clara Lehmann1,2,8, Peter Tessarz5,9, Janine Altmüller3, Peter Nürnberg2,3, Hamid Kashkar5,6, Florian Klein4,8, Manuel Koch10,11, Jan Rybniker1,2,8.
Abstract
Innate immunity triggers responsible for viral control or hyperinflammation in COVID-19 are largely unknown. Here we show that the SARS-CoV-2 spike protein (S-protein) primes inflammasome formation and release of mature interleukin-1β (IL-1β) in macrophages derived from COVID-19 patients but not in macrophages from healthy SARS-CoV-2 naïve individuals. Furthermore, longitudinal analyses reveal robust S-protein-driven inflammasome activation in macrophages isolated from convalescent COVID-19 patients, which correlates with distinct epigenetic and gene expression signatures suggesting innate immune memory after recovery from COVID-19. Importantly, we show that S-protein-driven IL-1β secretion from patient-derived macrophages requires non-specific monocyte pre-activation in vivo to trigger NLRP3-inflammasome signaling. Our findings reveal that SARS-CoV-2 infection causes profound and long-lived reprogramming of macrophages resulting in augmented immunogenicity of the SARS-CoV-2 S-protein, a major vaccine antigen and potent driver of adaptive and innate immune signaling.Entities:
Keywords: NLRP3; SARS-CoV-2; inflammasome; innate immunity; macrophage
Year: 2021 PMID: 34133077 DOI: 10.15252/emmm.202114150
Source DB: PubMed Journal: EMBO Mol Med ISSN: 1757-4676 Impact factor: 12.137